Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA).


Journal

Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388

Informations de publication

Date de publication:
12 2023
Historique:
medline: 24 4 2023
pubmed: 20 4 2023
entrez: 20 04 2023
Statut: ppublish

Résumé

Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US). Better understanding acceptability of treatment with injectable diacetylmorphine among people who use opioids (PWUO) in the US may expedite future initiatives designed to engage persons in this form of treatment should it become available. The purpose of this research is to examine factors associated with interest in treatment with injectable diacetylmorphine among a sample of PWUO in the US. Data are from a cross-sectional study of PWUO in Baltimore City, Maryland. Participants were given a brief description of treatment with injectable diacetylmorphine and then asked to rate their level of interest. We used Poisson regression with robust variance to assess factors associated with interest in treatment with injectable diacetylmorphine. The average age of participants was 48 years, 41% were women, and most (76%) identified as non-Hispanic, Black. The most commonly used substances were non-injection heroin (76%), opioid pain relievers (73%), and non-injection crack/cocaine (73%). Two-thirds of participants (68%) indicated interest in treatment with injectable diacetylmorphine. Factors significantly associated with interest in injectable diacetylmorphine treatment included: having at least a high school education (adjusted prevalence ratio [aPR]: 1.23; 95% confidence interval [CI]: 1.04-1.45), not having health insurance (aPR: 1.23; 95% CI: 1.06-1.44), having ever overdosed (aPR: 1.20; 95% CI: 1.01-1.42), and past utilization of medications for opioid use disorder (aPR: 1.22; 95% CI: 1.01-1.47). Recent non-injection cocaine use was inversely associated with interest in treatment with injectable diacetylmorphine (aPR 0.80; 95% CI: 0.68-0.94). The majority of participants reported interest in treatment with injectable diacetylmorphine. Given worsening trends in the addiction and overdose crisis in the US, treatment with injectable diacetylmorphine should be considered as another evidence-based option for treating OUD.KEY MESSAGESInterest in treatment with injectable diacetylmorphine was high among a sample of people who use opioids in the United States.Factors associated with increased interest in treatment with injectable diacetylmorphine included having at least a high school education, having ever overdosed, and not having health insurance.Past utilization of medications for opioid use disorder was associated with interest in treatment with injectable diacetylmorphine.

Identifiants

pubmed: 37078710
doi: 10.1080/07853890.2023.2196435
pmc: PMC10120460
doi:

Substances chimiques

Analgesics, Opioid 0
Heroin 70D95007SX
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2196435

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA046234
Pays : United States

Références

J Urban Health. 2019 Jun;96(3):442-451
pubmed: 30066174
Addiction. 2021 Feb;116(2):328-336
pubmed: 32533612
Addiction. 2019 Jan;114(1):103-111
pubmed: 30209840
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
Addiction. 2008 Jun;103(6):960-6; discussion 967-8
pubmed: 18422829
Drug Alcohol Depend. 2021 Oct 1;227:108984
pubmed: 34482044
J Subst Abuse Treat. 2006 Sep;31(2):203-11
pubmed: 16919749
Int J Drug Policy. 2022 Mar;101:103548
pubmed: 34920218
Lancet. 2001 Oct 27;358(9291):1417-23
pubmed: 11705488
J Gen Intern Med. 2006 Feb;21(2):193-5
pubmed: 16336624
Addiction. 2019 Aug;114(8):1379-1386
pubmed: 30851220
Br J Psychiatry. 2015 Jul;207(1):3-4
pubmed: 26135569
Harm Reduct J. 2020 Oct 13;17(1):67
pubmed: 33046103
J Opioid Manag. 2013 Mar-Apr;9(2):111-9
pubmed: 23709320
Harm Reduct J. 2021 Dec 18;18(1):134
pubmed: 34922561
Addiction. 2001 Aug;96(8):1113-25
pubmed: 11487418
Int J Drug Policy. 2010 Jan;21(1):36-42
pubmed: 18805686
N Engl J Med. 2009 Aug 20;361(8):777-86
pubmed: 19692689
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
J Stud Alcohol Drugs. 2020 Nov;81(6):740-749
pubmed: 33308403
J Addict Dis. 2016;35(1):22-35
pubmed: 26467975
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004145
pubmed: 18425898
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75
pubmed: 25747920
Drug Alcohol Depend. 2018 May 1;186:147-153
pubmed: 29573649
Drug Alcohol Rev. 2010 Jan;29(1):75-80
pubmed: 20078686
Addiction. 2022 Mar;117(3):518-531
pubmed: 34105206
J Addict Med. 2014 Sep-Oct;8(5):315-26
pubmed: 25221984
JAMA Netw Open. 2022 May 2;5(5):e2211363
pubmed: 35536575
Br J Psychiatry. 2015 Jul;207(1):5-14
pubmed: 26135571
Drug Alcohol Depend. 1999 Jun 1;55(1-2):25-33
pubmed: 10402146
Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv
pubmed: 17313907
Harm Reduct J. 2021 Apr 28;18(1):47
pubmed: 33910565
Clin Psychol Rev. 2010 Mar;30(2):155-66
pubmed: 19926374
Explor Res Clin Soc Pharm. 2021 Jun 04;2:100029
pubmed: 35481114
Int J Drug Policy. 2021 Dec;98:103426
pubmed: 34461411
MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443-4
pubmed: 25928470
J Subst Abuse Treat. 2020 Dec;119:108146
pubmed: 33138929
Drug Alcohol Depend. 2007 Feb 23;87(1):98-102
pubmed: 16959437
BMC Med Res Methodol. 2008 Feb 28;8:9
pubmed: 18307814
Addiction. 2010 Feb;105(2):300-8
pubmed: 19922517
CMAJ. 2019 Sep 23;191(38):E1049-E1056
pubmed: 31548191
BMJ. 2003 Aug 9;327(7410):310
pubmed: 12907482
Drug Alcohol Depend. 2006 Jun 28;83(2):104-10
pubmed: 16310322
Addict Behav. 2022 Apr;127:107215
pubmed: 34953432
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732
JAMA Health Forum. 2022 Nov 4;3(11):e224001
pubmed: 36331441

Auteurs

Sean T Allen (ST)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Kristin E Schneider (KE)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Saba Rouhani (S)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Rebecca Hamilton White (RH)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Miles Morris (M)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Jill Owczarzak (J)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Susan G Sherman (SG)

Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH